Clinical Trials Not Required For Lidoderm Generics, FDA Tells Endo
Executive Summary
The agency distinguishes the lidocaine pain patch from topical dermatological drugs intended to treat skin diseases in rejecting Endo’s call that ANDA sponsors demonstrate bioequivalence through clinical trials, rather than merely pharmacokinetic studies.